Bryan Kay

7 POSTS 0 COMMENTS

VEITH 2021: Two-year follow-up data from EVAS2 IDE study delivered

The confirmatory EVAS2 clinical study to evaluate the safety and effectiveness of Endologix's Nellix endovascular aneurysm sealing system (EVAS) for the treatment of infrarenal...

EMINENT one-year results show “superior” primary patency rate for Eluvia DES...

One-year results presented at Vascular Interventional Advances (VIVA) 2021 (5–7 October, Las Vegas, USA) from the EMINENT trial demonstrated the superiority of the Eluvia...

VIVA 2021: Consensus established for appropriate use of IVUS in peripheral...

A worldwide committee of 40 cross-speciality medical experts achieved the first-ever consensus for the appropriate use of intravascular ultrasound (IVUS) in peripheral vascular disease...

IN.PACT AV DCB sustained “superior” effectiveness in subgroups with high reintervention...

Several subgroups of patients treated with the IN.PACT AV drug-coated balloon (DCB; Medtronic) for arteriovenous fistulas (AVFs) demonstrated a “statistically significant” higher rate of...

VIVA 2021: IVL “consistently” treats real-world calcium in multiple peripheral vessel...

An interim analysis from the DISRUPT PAD III observational study showed that intravascular lithotripsy (IVL; Shockwave Medical) performs “consistently well” across challenging peripheral vessels,...

Two-year Ranger DCB data demonstrate “sustained, high rate” of device efficacy

Patients treated with the Ranger drug-coated balloon (DCB; Boston Scientific) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year...

VIVA 2021: IN.PACT Admiral DCB found to provide “high five-year freedom...

Real-world data drawn from the IN.PACT Global study looking at five-year freedom from clinically-driven target lesion revascularisation (TLR) among prespecified chronic total occlusion (CTO),...